Enzyme replacement therapy in Gaucher's disease: a rapid, high-yield method for purification of glucocerebrosidase.
Gaucher's disease is caused by a deficiency of the lysosomal enzyme glucocerebrosidase (glucosylceramidase; D-glucosyl-N-acylsphingosine glucohydrolase, EC 3.2.1.45); this disorder has been a leading candidate for enzyme replacement trials. A rapid, high-yield method for purification of glucocerebrosidase has been developed. Detergent extraction of human placenta was followed by salt fractionation, concanavalin A-Sepharose chromatography, organic solvent precipitation, and affinity chromatography on phosphatidylserine-agarose; the total yield is 60% with 6000-fold purification. Purified glucocerebrosidase has been administered intravenously to a volunteer Gaucher's patient on two separate occasions. For the first injection, the enzyme was entrapped in resealed erythrocytes; for the second injection, the enzyme was given without any carrier. The enzyme infusions caused no untoward effects.
D004910:Erythrocyte Membrane; D005776:Gaucher Disease / Q000188:drug therapy*; D005959:Glucosidases / Q000302:isolation & purification*; D005962:Glucosylceramidase / Q000008:administration & dosage / Q000302:isolation & purification* / Q000627:therapeutic use; D006801:Humans; D007275:Injections, Intravenous; D008722:Methods; D010920:Placenta / Q000201:enzymology
D005959:Glucosidases; D005962:Glucosylceramidase